Search results for: bisphosphonate

Do Older Women Who Use Bisphosphonates Need Fewer Knee Replacements?

Reuters Staff | October 19, 2017

NEW YORK (Reuters Health)—The rate of knee replacement surgery among older women with knee osteoarthritis is lower in those who take bisphosphonates than in those who don’t, according to a database study. Knee osteoarthritis accounts for 97% of all knee replacement surgeries. Trials of bisphosphonates in knee osteoarthritis have yielded conflicting results. To learn more,…

Switching from Bisphosphonates to Teriparatide May Improve BMD in Women with RA

Scott Baltic | August 19, 2017

NEW YORK (Reuters Health)—Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report. Researchers in Japan conducted an 18-month observational study of more than 175 women with RA (mean age: 66) who remained on oral bisphosphonates, switched to denosumab (DMAb),…

Biochemical Insights into Progeria Syndrome Identify Bisphosphonates, Statins as Possible Candidate Drugs to Halt Aging

Simon M. Helfgott, MD | August 10, 2016

Can We Stay Forever Young? May your heart always be joyful And may your song always be sung May you stay forever young Forever Young —Bob Dylan Beneath the rubric of orphan diseases reside some rare conditions and others that are extraordinarily uncommon. These are the diseases that most physicians either never to get to…

GI Side Effects Leading Reason for Bisphosphonate Nonadherence

Reuters Staff | July 6, 2016

NEW YORK (Reuters Health)—Gastrointestinal side effects are the most common reason osteoporotic women cite for nonadherence to oral bisphosphonate therapy, according to a new survey. “Our findings highlight the importance of low tolerability to nonadherence with osteoporosis therapy and underlines patients’ poor awareness and suboptimal physicians’ involvement in conveying the importance of this therapy,” Dr….

New Bisphosphonate Therapy Recommendations for Postmenopausal Osteoporosis

Kathy Holliman | May 13, 2016

A task force of the American Society for Bone and Mineral Research (ASBMR) has released new recommendations delineating the potential benefits and risks of prolonged therapy with oral and IV bisphosphonate therapy and providing guidance on duration of bisphosphonate therapy for postmenopausal osteoporosis.1 The task force makes clear that data and clinical experience on which…

Do Bisphosphonates Increase Risk of Carpal Tunnel Syndrome?

Lara C. Pullen, PhD | March 7, 2016

In a large-scale study, researchers demonstrated that the use of bisphosphonates in postmenopausal women is associated with an increased risk of carpal tunnel syndrome, in addition to other known risks (e.g., incapacitating bone, joint and/or musculoskeletal pain, and osteonecrosis of the jaw)…

FDA Issues Safety Alerts for Bisphosphonates & SGLT2 Inhibitors

Michele B. Kaufman, PharmD, BCGP | May 20, 2015

Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…